Simsen Diagnostics
Simsen Diagnostics utilizes SiMSen sequencing and two-tailed PCR to provide personalized cancer DNA testing from blood samples, enabling precise monitoring of unique tumor mutations. This technology enhances sensitivity and specificity in cancer detection, addressing the limitations of standardized testing methods.
- Biotechnology
Funding
Raised to date
$970KRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Standardized cancer testing methods may lack the sensitivity to detect the unique DNA mutations present in each patient's tumor, potentially leading to delayed or inaccurate monitoring of the disease. This can result in suboptimal treatment decisions and poorer patient outcomes.
Solution
Simsen Diagnostics offers Simsen® Personal, a personalized cancer DNA testing service that utilizes SiMSen sequencing and two-tailed PCR to monitor unique tumor mutations from blood samples. By creating a customized assay for each patient, Simsen® Personal achieves enhanced sensitivity and specificity in detecting circulating tumor DNA (ctDNA), enabling earlier and more precise monitoring of cancer progression or recurrence. The technology aims to detect cancer years before standard-of-care tools. This personalized approach allows for more informed treatment strategies and improved patient management.
Target Audience
The primary target audience includes oncologists, cancer centers, and pharmaceutical companies involved in cancer research and treatment, particularly those focused on personalized medicine and early cancer detection.
Features
- SiMSen sequencing technology for ultrasensitive detection of ctDNA
- Two-tailed PCR method to enhance specificity and minimize false positives
- Personalized assay design based on the unique mutational profile of each patient's tumor
- Tumor-informed approach for monitoring known mutations
- Liquid biopsy analysis using blood samples for minimally invasive monitoring